MA29567B1 - (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl) amino]-1,3-thiazol-4(5h)-one - Google Patents

(5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl) amino]-1,3-thiazol-4(5h)-one

Info

Publication number
MA29567B1
MA29567B1 MA30514A MA30514A MA29567B1 MA 29567 B1 MA29567 B1 MA 29567B1 MA 30514 A MA30514 A MA 30514A MA 30514 A MA30514 A MA 30514A MA 29567 B1 MA29567 B1 MA 29567B1
Authority
MA
Morocco
Prior art keywords
quinoxalinylmethylidene
thiazol
dichlorophenyl
amino
compound
Prior art date
Application number
MA30514A
Other languages
English (en)
Inventor
Kevin J Duffy
Duke M Fitch
Beth A Norton
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA29567B1 publication Critical patent/MA29567B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

EST INVENTÉ LE COMPOSÉ (5Z)-5-(6-QUINOXALINYLMÉTHYLIDÈNE)-2-[(2,6-DICHLOROPHÉNYL)AMINO]-1,3-THIAZOL-4(5H)-ONE, ET/OU SES SELS, HYDRATES, SOLVATES ET PROMÉDICAMENTS PHARMACEUTIQUEMENT ACCEPTABLES. L¿INVENTION CONCERNE ÉGALEMENT DES COMPOSITIONS PHARMACEUTIQUES CONTENANT CE COMPOSÉ, DES MÉTHODES DE PRÉPARATION DE CE COMPOSÉ AINSI QUE DE SES SELS, HYDRATES, SOLVATES ET PROMÉDICAMENTS PHARMACEUTIQUEMENT ACCEPTABLES. L¿INVENTION CONCERNE ÉGALEMENT DES PROCÉDÉS D¿UTILISATION DE CE COMPOSÉ EN TANT QU¿INHIBITEUR DE PROTÉINES HYAK3.
MA30514A 2005-06-08 2007-12-26 (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl) amino]-1,3-thiazol-4(5h)-one MA29567B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68867105P 2005-06-08 2005-06-08

Publications (1)

Publication Number Publication Date
MA29567B1 true MA29567B1 (fr) 2008-06-02

Family

ID=37532819

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30514A MA29567B1 (fr) 2005-06-08 2007-12-26 (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl) amino]-1,3-thiazol-4(5h)-one

Country Status (21)

Country Link
US (1) US7674792B2 (fr)
EP (1) EP1888531A4 (fr)
JP (1) JP2008543770A (fr)
KR (1) KR20080014017A (fr)
CN (1) CN101193863A (fr)
AP (1) AP2007004241A0 (fr)
AR (1) AR054059A1 (fr)
AU (1) AU2006258032A1 (fr)
BR (1) BRPI0611096A2 (fr)
CA (1) CA2611480A1 (fr)
EA (1) EA200702457A1 (fr)
IL (1) IL187423A0 (fr)
MA (1) MA29567B1 (fr)
MX (1) MX2007015572A (fr)
NO (1) NO20080130L (fr)
NZ (1) NZ563421A (fr)
PE (1) PE20070083A1 (fr)
TW (1) TW200716580A (fr)
UY (1) UY29581A1 (fr)
WO (1) WO2006135712A2 (fr)
ZA (1) ZA200709813B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543769A (ja) * 2005-06-08 2008-12-04 スミスクライン・ビーチャム・コーポレイション （５ｚ）−５−（６−キノキサリニルメチリデン）−２−［（２，４，６−トリクロロフェニル）アミノ］−１，３−チアゾール−４（５ｈ）−オン
US20100286041A1 (en) * 2007-03-22 2010-11-11 Smithkline Beecham Corporation (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one
EP2164494A4 (fr) * 2007-06-01 2010-06-02 Glaxosmithkline Llc Procédés de traitement

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5545648A (en) 1978-09-29 1980-03-31 Teikoku Hormone Mfg Co Ltd 2-formyldibenzazepin derivative and its preparation
JP2539504B2 (ja) 1987-03-11 1996-10-02 鐘淵化学工業株式会社 ヒドロキシスチレン誘導体
US5089516A (en) 1987-03-11 1992-02-18 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha 1-phenyl-3,5-pyrazolidinedione hydroxystyrene compounds which have tyrosine kinase inhibiting activity
US5202341A (en) 1987-03-11 1993-04-13 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene compounds having tyrosine kinase inhibiting activity
JPH0197926A (ja) 1987-10-09 1989-04-17 Idemitsu Kosan Co Ltd 有機非線型光学材料
DD270072A1 (de) 1988-03-14 1989-07-19 Univ Halle Wittenberg Verfahren zur herstellung von 5-aryliden- hoch 2-thiazolin-4-onen
US5306822A (en) 1988-05-25 1994-04-26 Warner-Lambert Company Arylmethylenyl derivatives of oxazolidinone
US5145753A (en) 1989-09-12 1992-09-08 Mitsubishi Jukogyo Kabushiki Kaisha Solid electrolyte fuel cell
US5053420A (en) 1989-10-13 1991-10-01 Pershadsingh Harrihar A Thiazolidine derivatives for the treatment of hypertension
GB9004483D0 (en) 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
US5143928A (en) 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
JPH052200A (ja) 1990-09-28 1993-01-08 Toshiba Corp 有機非線形光学材料
EP0554834B1 (fr) 1992-02-03 1998-06-03 Fuji Photo Film Co., Ltd. Procédé de dispersion d'un colorant et matériau photographique à l'halogénure d'argent contenant un colorant
JP2835246B2 (ja) 1992-06-02 1998-12-14 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
CZ181493A3 (en) 1992-09-10 1994-03-16 Lilly Co Eli The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease
DE69333314D1 (de) 1992-09-11 2004-01-08 Agfa Gevaert Nv Photographisches Element,das einen Filterfarbstoff enthält, für Schnellverarbeitungs-Verwendungen
DE69331891T2 (de) 1992-09-11 2002-10-31 Agfa-Gevaert, Mortsel Photographisches Element,das einen Filterfarbstoff enthält, für Schnellverarbeitungs-Verwendungen
JPH06128234A (ja) 1992-10-19 1994-05-10 Fuji Photo Film Co Ltd 不斉炭素原子を有する化合物およびそれからなる非線形光学材料
US5554767A (en) 1993-05-21 1996-09-10 Warner-Lambert Company Alpha-mercaptoacrylic acid derivatives having calpain inhibitory activity
US6251928B1 (en) 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
EP0687573A1 (fr) 1994-06-13 1995-12-20 Agfa-Gevaert N.V. Elément donneur de colorant pour utilisation dans un procédé de transfert thermique de colorant
JP3871354B2 (ja) 1994-07-29 2007-01-24 株式会社フジモト・コーポレーション 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体
JPH08109176A (ja) 1994-10-07 1996-04-30 Torii Yakuhin Kk イソローダニンｎ酢酸誘導体
IL117208A0 (en) 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
US5618835A (en) 1996-02-01 1997-04-08 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
JPH09255669A (ja) 1996-03-22 1997-09-30 Hisamitsu Pharmaceut Co Inc 新規なベンジリデン誘導体
US5958957A (en) 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US6632947B2 (en) 1997-02-18 2003-10-14 Smithkline Beecham Plc Process for the preparation of substituted thiazolidinedione
US6011031A (en) 1997-05-30 2000-01-04 Dr. Reddy's Research Foundation Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
WO1999059586A1 (fr) 1998-05-19 1999-11-25 Regents Of The University Of California Derives de thiazolidine et d'oxazolidine pour le traitement d'infarctus du myocarde aigus et pour l'inhibition de l'apoptose des cardiomyocytes
WO2000018748A1 (fr) 1998-09-30 2000-04-06 Roche Diagnostics Gmbh Derives de rhodanine utiles pour le traitement et la prevention de troubles metaboliques des os
US6221613B1 (en) 1998-12-31 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
US6689491B1 (en) 1999-02-08 2004-02-10 Fuji Photo Film Co., Ltd. Luminescent device material, luminescent device using the same, and amine compound
US6372742B1 (en) 1999-07-01 2002-04-16 Geron Corporation Substituted indole compounds and methods of their use
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
US6720345B1 (en) 1999-11-05 2004-04-13 Smithkline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
US7005288B1 (en) * 1999-11-10 2006-02-28 Novozymes A/S Fungamyl-like alpha-amylase variants
JP2001348520A (ja) 2000-04-03 2001-12-18 Fuji Photo Film Co Ltd メチン化合物、固体微粒子分散物、インクジェット用記録液、およびインクジェット記録方法
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
EP1299362A4 (fr) 2000-07-05 2004-11-03 Synaptic Pharma Corp Antagonistes selectifs des recepteurs (mch1) d'hormone-1 de concentration de la melanine et utilisation de ceux-ci
US6410734B1 (en) 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
DE10115227A1 (de) 2001-03-28 2002-12-19 Bayer Ag Optischer Datenträger enthaltend in der Informationsschicht eine lichtabsorbierende Verbindung mit mehreren chromophoren Zentren
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
JP2004526756A (ja) 2001-04-06 2004-09-02 スミスクライン ビーチャム コーポレーション ｈＹＡＫ１及びｈＹＡＫ３キナーゼのキノリン阻害剤
TW200304375A (en) 2001-12-06 2003-10-01 Maxia Pharmaceuticals Inc 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer
US20050019825A9 (en) 2002-03-15 2005-01-27 Qing Dong Common ligand mimics: pseudothiohydantoins
EP1556379A4 (fr) 2002-10-16 2007-06-13 Smithkline Beecham Corp Composes chimiques
EP1567112B1 (fr) 2002-11-22 2008-10-15 Smithkline Beecham Corporation THIAZOLIDIN-4-ONES POUR INHIBER LES PROTÉINES hYAK3
US7645421B2 (en) * 2003-06-20 2010-01-12 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
DE602004022170D1 (de) 2003-07-28 2009-09-03 Merck Serono Sa Coinsins 2-imino-4-(thio)oxo-5-polycyclovinylazoline zur verwendung als pi3-kinase-inhibtoren
EP1654380A4 (fr) 2003-08-14 2009-09-09 Insight Biopharmaceuticals Ltd Methodes et compositions pharmaceutiques servant a moduler l'activation d'heparanase et leurs utilisations
US20090270456A1 (en) 2004-01-09 2009-10-29 Masaichi Hasegawa Novel chemical compounds
WO2005076854A2 (fr) 2004-02-04 2005-08-25 Smithkline Beecham Corporation Nouveaux composes chimiques
WO2005082363A1 (fr) 2004-02-20 2005-09-09 Board Of Regents, The University Of Texas System Composes de thiazolone permettant de traiter le cancer
EP1718642A4 (fr) 2004-02-25 2010-11-24 Glaxosmithkline Llc Nouveaux composes chimiques
WO2006002828A1 (fr) 2004-07-01 2006-01-12 F. Hoffmann-La Roche Ag Quinoline thiazolinones a activite antiproliferante anti-cdk1
JP2008504324A (ja) 2004-07-01 2008-02-14 エフ．ホフマン−ラ　ロシュ　アーゲー チアゾリノン非置換型キノリン
US7253285B2 (en) 2004-09-17 2007-08-07 Hoffmann-La Roche Inc. Thiazolinone 4-monosubstituted quinolines
AR053602A1 (es) 2005-05-03 2007-05-09 Smithkline Beecham Corp Compuesto de 2- arilamino -4-oxo-1,3-tiazol-5(4h)- substituido, composicion farmaceutica que lo comprende, proceso para prepararla y uso del compuesto para preparar un medicamento
JP2008545690A (ja) 2005-05-23 2008-12-18 スミスクライン・ビーチャム・コーポレイション 新規化合物
JP2008543769A (ja) 2005-06-08 2008-12-04 スミスクライン・ビーチャム・コーポレイション （５ｚ）−５−（６−キノキサリニルメチリデン）−２−［（２，４，６−トリクロロフェニル）アミノ］−１，３−チアゾール−４（５ｈ）−オン

Also Published As

Publication number Publication date
US7674792B2 (en) 2010-03-09
EP1888531A2 (fr) 2008-02-20
NZ563421A (en) 2010-07-30
EP1888531A4 (fr) 2009-06-17
UY29581A1 (es) 2006-11-30
CN101193863A (zh) 2008-06-04
ZA200709813B (en) 2008-09-25
TW200716580A (en) 2007-05-01
BRPI0611096A2 (pt) 2010-12-21
PE20070083A1 (es) 2007-01-27
KR20080014017A (ko) 2008-02-13
AU2006258032A1 (en) 2006-12-21
WO2006135712A3 (fr) 2007-06-28
AP2007004241A0 (en) 2007-12-31
EA200702457A1 (ru) 2008-04-28
AR054059A1 (es) 2007-05-30
MX2007015572A (es) 2008-02-25
US20070179144A1 (en) 2007-08-02
JP2008543770A (ja) 2008-12-04
WO2006135712A2 (fr) 2006-12-21
NO20080130L (no) 2008-01-08
IL187423A0 (en) 2008-02-09
CA2611480A1 (fr) 2006-12-21

Similar Documents

Publication Publication Date Title
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
MX2009005604A (es) Inhibidores espiro cetona de acetil-coa carboxilasa.
NO20070529L (no) Kinazolindionderivater som parp-inhibitorer
MA31763B1 (fr) Inhibiteurs de kinase de type polo
MA30781B1 (fr) Inhibiteur de kinase
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
ATE479687T1 (de) Kinaseinhibitoren
EP1620411A4 (fr) Inhibiteurs de l'activite de l'akt
PL1899329T3 (pl) Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych
EA200702498A1 (ru) N-(пиридин-2-ил)сульфонамидные производные
WO2007011833A3 (fr) Inhibiteurs de spiropiperidine beta-secretase pour le traitement de la maladie d'alzheimer
WO2007139856A3 (fr) Inhibiteurs de métalloprotéases hétérobicycliques
WO2006044497A3 (fr) Composes de spiropiperidine utilises comme inhibiteurs de beta-secretase en vue du traitement de la maladie d'alzheimer
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
TW200517106A (en) Sustained release pharmaceutical compositions
WO2008054698A3 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
MA30757B1 (fr) Inhibiteurs de l'akt (proteine kinase b)
WO2003065987A3 (fr) Inhibiteurs de granzyme b
AR083417A1 (es) Composiciones farmaceuticas que contienen un dgat1 inhibidor
MA32343B1 (fr) Pyrimidyle cyclopentane hydroxylé en tant qu'inhibiteur de protéine kinase akt
BR0317284A (pt) Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno
MA30523B1 (fr) Compose tricylique et utilisation pharmaceutique de celui-ci
MA29567B1 (fr) (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl) amino]-1,3-thiazol-4(5h)-one